{"id":"rass-inhibitors-and-or-ras-blockers","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Hypotension"},{"rate":"10-20","effect":"Cough (ACE inhibitors)"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Renal function impairment"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"These agents work by blocking either angiotensin II formation (ACE inhibitors, direct renin inhibitors) or angiotensin II receptor binding (ARBs), or by blocking aldosterone (aldosterone antagonists). By inhibiting this hormonal cascade, they reduce peripheral vascular resistance, decrease blood volume, and improve cardiac remodeling, making them effective for hypertension and heart failure.","oneSentence":"RASS inhibitors and RAS blockers suppress the renin-angiotensin-aldosterone system to reduce vasoconstriction, lower blood pressure, and decrease sodium retention.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:52:16.023Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure"},{"name":"Chronic kidney disease"},{"name":"Post-myocardial infarction"}]},"trialDetails":[{"nctId":"NCT01198275","phase":"PHASE3","title":"n-3 Polyunsaturated Fatty Acids (PUFAs) in the Prevention of Atrial Fibrillation","status":"COMPLETED","sponsor":"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","startDate":"2006-01","conditions":"Atrial Fibrillation","enrollment":199}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["renin-angiotensin-aldosterone system inhibitor"],"phase":"phase_3","status":"active","brandName":"RASS inhibitors and/or RAS blockers","genericName":"RASS inhibitors and/or RAS blockers","companyName":"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","companyId":"azienda-socio-sanitaria-territoriale-degli-spedali-civili-di-brescia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"RASS inhibitors and RAS blockers suppress the renin-angiotensin-aldosterone system to reduce vasoconstriction, lower blood pressure, and decrease sodium retention. Used for Hypertension, Heart failure, Chronic kidney disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}